Literature DB >> 19235857

Multivalent interactions with gp120 are required for the anti-HIV activity of Cyanovirin.

Yinan Liu1, Jacob R Carroll, Lindsey A Holt, James McMahon, Barbara Giomarelli, Giovanna Ghirlanda.   

Abstract

Cyanovirin-N (CV-N) is a cyanobacterial lectin that binds to specific oligomannoses on the surface of gp120, resulting in nanomolar antiviral activity against HIV. In its monomeric form, CV-N contains two functional carbohydrate-binding domains, A and B. When refolded at high concentration, the protein can form a domain-swapped dimer. To clarify the role of multiple-binding sites in CV-N, we previously designed a monomeric mutant, P51G-m4-CVN, in which the binding site on domain A was rendered ineffective by four mutations (m4); in addition, a hinge region mutation (P51G) hinders the formation of a domain swapped dimer. The protein bound gp120 with diminished affinity and was completely inactive against HIV. Here, we present two mutants, DeltaQ50-m4-CVN and S52P-m4-CVN, which fold exclusively as domain-swapped dimers while containing the four mutations that abolish domain A. The dimers contain two intact B domains, thus restoring multivalency. DeltaQ50-m4-CVN and S52P-m4-CVN bind gp120 at low-nanomolar concentrations and recover in part the antiviral activity of wt CV-N. These results indicate that the number of carbohydrate binding domains, rather than their identity, is crucial to CV-N functionality. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235857      PMCID: PMC6961781          DOI: 10.1002/bip.21173

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  36 in total

Review 1.  Inhibition of HIV entry by carbohydrate-binding proteins.

Authors:  J Balzarini
Journal:  Antiviral Res       Date:  2006-03-09       Impact factor: 5.970

Review 2.  Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction.

Authors:  J C Sacchettini; L G Baum; C F Brewer
Journal:  Biochemistry       Date:  2001-03-13       Impact factor: 3.162

3.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside.

Authors:  David C Williams; Jae Young Lee; Mengli Cai; Carole A Bewley; G Marius Clore
Journal:  J Biol Chem       Date:  2005-06-03       Impact factor: 5.157

5.  A semiautomated multiparameter approach for anti-HIV drug screening.

Authors:  R J Gulakowski; J B McMahon; P G Staley; R A Moran; M R Boyd
Journal:  J Virol Methods       Date:  1991-06       Impact factor: 2.014

Review 6.  Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?

Authors:  Jan Balzarini
Journal:  Antivir Chem Chemother       Date:  2007

Review 7.  Structural studies of algal lectins with anti-HIV activity.

Authors:  Natasza E Ziółkowska; Alexander Wlodawer
Journal:  Acta Biochim Pol       Date:  2006-11-27       Impact factor: 2.149

8.  Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.

Authors:  Harumi Chiba; Junji Inokoshi; Hideki Nakashima; Satoshi Omura; Haruo Tanaka
Journal:  Biochem Biophys Res Commun       Date:  2004-03-26       Impact factor: 3.575

9.  Domain-swapped structure of a mutant of cyanovirin-N.

Authors:  Istvan Botos; Toshiyuki Mori; Laura K Cartner; Michael R Boyd; Alexander Wlodawer
Journal:  Biochem Biophys Res Commun       Date:  2002-05-31       Impact factor: 3.575

Review 10.  Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy.

Authors:  Jan Balzarini
Journal:  Nat Rev Microbiol       Date:  2007-08       Impact factor: 60.633

View more
  15 in total

1.  Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Authors:  Jennifer R Keeffe; Priyanthi N P Gnanapragasam; Sarah K Gillespie; John Yong; Pamela J Bjorkman; Stephen L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-28       Impact factor: 11.205

2.  Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Olof Ramström; Angela M Gronenborn; Mingdi Yan
Journal:  Chem Commun (Camb)       Date:  2011-06-30       Impact factor: 6.222

3.  A flexible docking scheme efficiently captures the energetics of glycan-cyanovirin binding.

Authors:  Ashini Bolia; Brian W Woodrum; Angelo Cereda; Melissa A Ruben; Xu Wang; S Banu Ozkan; Giovanna Ghirlanda
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

4.  Solution and crystal molecular dynamics simulation study of m4-cyanovirin-N mutants complexed with di-mannose.

Authors:  Ivan I Vorontsov; Osamu Miyashita
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

5.  Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

Authors:  Jan Balzarini; Katrien O François; Kristel Van Laethem; Bart Hoorelbeke; Marleen Renders; Joeri Auwerx; Sandra Liekens; Toshikazu Oki; Yasuhiro Igarashi; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

6.  Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.

Authors:  Bibek Parajuli; Kriti Acharya; Harry C Bach; Bijay Parajuli; Shiyu Zhang; Amos B Smith; Cameron F Abrams; Irwin Chaiken
Journal:  Biochem J       Date:  2018-03-09       Impact factor: 3.857

7.  Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate.

Authors:  Joseph Calvin Kouokam; Dana Huskens; Dominique Schols; Andrew Johannemann; Shonna K Riedell; Wendye Walter; Janice M Walker; Nobuyuki Matoba; Barry R O'Keefe; Kenneth E Palmer
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

8.  Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity.

Authors:  Tinoush Moulaei; Shilpa R Shenoy; Barbara Giomarelli; Cheryl Thomas; James B McMahon; Zbigniew Dauter; Barry R O'Keefe; Alexander Wlodawer
Journal:  Structure       Date:  2010-09-08       Impact factor: 5.006

Review 9.  Algal lectins as potential HIV microbicide candidates.

Authors:  Dana Huskens; Dominique Schols
Journal:  Mar Drugs       Date:  2012-07-10       Impact factor: 6.085

10.  Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 by targeting the glycan ligand.

Authors:  Jia Chen; Dane Huang; Wei Chen; Chaowan Guo; Bo Wei; Chongchao Wu; Zhou Peng; Jun Fan; Zhibo Hou; Yongsheng Fang; Yifei Wang; Kaio Kitazato; Guoying Yu; Chunbin Zou; Chuiwen Qian; Sheng Xiong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.